Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.40 |
| ▸ | RELA | Q04206 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432893 | 0.81 | ALOX5 (0.41) | ALOX5NISCHNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13051430 | 0.81 | ALOX5 (0.41) | ALOX5NISCHNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL276641 | 0.74 | ALOX5 (0.49) | ALOX5NISCHNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23674675 | 0.73 | ALOX5 (0.42) | ALOX5NISCHNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4687524 | 0.69 | ALOX5 (0.45) | ALOX5NISCHNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2302094 | 0.69 | MAOA (0.43) | PTGS2MAOBMAOA | |
| SCHEMBL294209 | 0.69 | ALOX5 (0.45) | ALOX5NISCHNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2013567 | 0.69 | ALOX5 (0.45) | ALOX5NISCHNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL224498 | 0.69 | ALOX5 (0.45) | ALOX5NISCHNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1650298 | 0.69 | ALOX5 (0.49) | ALOX5NISCHNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109053700-A | A kind of hypochlorous acid ratio fluorescent probe and its application | 山东大学 | 2018-12-21 | — | — | CN | claimed |
| CN-108997289-A | It is a kind of target fat drips hypochlorous acid ratio fluorescent probe and its application | 山东大学 | 2018-12-14 | — | — | CN | claimed |
| EP-1539142-A2 | USE OF AN AMYLOID BETA VACCINATION IN COMBINATION WITH A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF ALZHEIMER S DISEASE | Pharmacia Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| WO-2004014367-A2 | USE OF AN AMYLOID BETA VACCINATION IN COMBINATION WITH A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PHARMACIA CORPORATION (US) | 2004-02-19 | — | — | WO | claimed |
| CN-104250228-B | Monomer for hard mask composition and the hard mask composition including the monomer and the method for forming pattern using it | 第一毛织株式会社 | 2019-05-10 | — | — | CN | disclosed |
| CN-109053700-A | A kind of hypochlorous acid ratio fluorescent probe and its application | 山东大学 | 2018-12-21 | — | — | CN | disclosed |
| CN-108997289-A | It is a kind of target fat drips hypochlorous acid ratio fluorescent probe and its application | 山东大学 | 2018-12-14 | — | — | CN | disclosed |
| US-8394974-B2 | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110263642-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | FIBROGEN, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2341904-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | Fibrogen, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20100081808-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-2003135-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008009741-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2008-01-24 | — | — | WO | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1732929-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | Nissan Chemical Industries, Ltd. (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090357-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-29 | — | — | WO | disclosed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081808-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | OSTC, EEF1D, SQLE | ALOX5 43/4885NISCH 888/4885NPC1 4142/4885 |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | CYP2C19, CYP2C9, CYP1A2 | ALOX5 609/4885NISCH 430/4885NPC1 3663/4885 |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | ALOX5 1068/4885NISCH 2290/4885NPC1 3638/4885 |
| US-20110263642-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | PMP22, MAG, NEFM | ALOX5 239/4885NISCH 1557/4885NPC1 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.